What is LumiThera?
LumiThera operates as a commercial-stage medical device enterprise focused on the intersection of light-based technology and clinical ophthalmology. The company's flagship innovation, the Valeda Light Delivery System, utilizes PBM to stimulate cellular function in the retina, offering a novel therapeutic pathway for visual disorders that have historically lacked effective treatment options. By providing eyecare professionals with advanced, non-invasive tools, LumiThera is effectively shifting the paradigm of care for aging populations prone to degenerative ocular conditions. Their market position is bolstered by a robust history of capital raises, enabling the transition from early-stage research to widespread clinical adoption.
How much funding has LumiThera raised?
LumiThera has raised a total of $34.7M across 6 funding rounds:
Private Equity
$5M
Series A
$4.5M
Series B
$5.5M
Series C
$14M
Debt
$214K
Debt
$5.5M
Private Equity (2016): $5M, investors not publicly disclosed
Series A (2016): $4.5M, investors not publicly disclosed
Series B (2017): $5.5M supported by WaterStone Capital
Series C (2020): $14M featuring WaterStar Capital, Nikon Corporation, Water Star Mercury Fund, Imagine Ventures, Keiretsu Capital, and Celeste Management
Debt (2021): $214K backed by PPP
Debt (2022): $5.5M with participation from Leste Clearway Capital and Serengeti Asset Management
Key Investors in LumiThera
Serengeti Asset Management
A value-driven opportunistic investment firm specializing in private credit, venture funding, and structured equity for companies facing complex financial requirements.
Leste Clearway Capital
A private equity and venture capital firm focused on providing growth capital to emerging enterprises within the United States.
Keiretsu Capital
A prominent investment organization comprised of angel investors, venture capitalists, and institutional partners dedicated to supporting high-growth startups.
What's next for LumiThera?
Following this major strategic investment, LumiThera is expected to prioritize the expansion of its commercial infrastructure and the scaling of its Valeda platform across international markets. The company's strategic roadmap likely includes deepening its clinical evidence base to support broader regulatory approvals and enhancing its distribution network to ensure that PBM technology becomes a standard of care in clinical settings. As the firm moves beyond its current growth phase, the focus will remain on operational excellence and the continued validation of its technology as a primary intervention for age-related blindness, ensuring long-term value creation for its diverse base of institutional and strategic backers.
See full LumiThera company page
